

MT2025-50: An Open-label, Multicenter Phase 1/2 Study to Evaluate the Safety and Efficacy of AB-3028 in Patients with Castration Resistant Prostate Cancer (CRPC)

Status: Recruiting

Eligibility Criteria

Sex: Male

Age Group: 18 years and over

Inclusion Criteria:

- confirmed adenocarcinoma of the prostate - progressive metastatic castration-resistant prostate cancer - prior treatment with at least 1 novel androgen receptor pathway inhibitor (ARPI) therapy - see link to clinicaltrials.gov for complete Inclusion criteria

Exclusion Criteria:

- Central nervous system (CNS) metastatic disease, leptomeningeal disease, or spinal cord compression - unwilling to participate in an extended period of monitoring for side effects - see link to clinicaltrials.gov for complete Exclusion criteria

Conditions & Interventions

Interventions:

Biological: AB-3028

Keywords:

Clinics and Surgery Center (CSC)

More Information

Description: The main purpose of first part of this study is to see if an experimental cell therapy called AB-3028 is a safe and effective treatment for people with metastatic castration resistant prostate cancer (mCRPC). AB-3028 is a personalized cell therapy made from your own white blood cells. The main goals of the first part are to test the safety of the treatment at different dose levels and find the recommended dose for the second part of the study.

Study Contact: Nicholas Zorko - zorko004@umn.edu

Principal Investigator: Nicholas Zorko

Phase: PHASE1

IRB Number: STUDY00027246

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.